# T790M Plasma Testing Methodology Comparison and Clinical Validation

> **NCT02997501** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 256 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **PROCEDURE:** T790M+ Testing
- **PROCEDURE:** Baseline Visit Blood & Urine Testing
- **PROCEDURE:** Baseline ECG
- **PROCEDURE:** Visual Slit-Lamp Testing
- **DRUG:** AZD9291 Dosing
- **PROCEDURE:** Plasma AZD9291 testing

## Key facts

- **NCT ID:** NCT02997501
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-23
- **Primary completion:** 2018-10-24
- **Final completion:** 2018-10-24
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2024-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02997501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02997501, "T790M Plasma Testing Methodology Comparison and Clinical Validation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02997501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*